研究显示,螺旋醇内酯并没有改善心脏发作后的结果,但可能会减少新的心衰竭。 Spironolactone didn't improve outcomes post-heart attack but may reduce new heart failures, study shows.
CLEAR SYNERGY试验发现,在心脏病发作并经过特定程序之后,血丙醇内酯没有改善病人的治疗结果。 The CLEAR SYNERGY trial found that spironolactone did not improve outcomes for patients after a heart attack who underwent a specific procedure. 虽然它没有降低心血管死亡或心脏衰竭的风险,但它显示出在病人继续服药时减少新的或恶化的心脏衰竭的潜在好处。 While it didn't reduce the risk of cardiovascular death or heart failure, it showed a potential benefit in reducing new or worsening heart failure when patients stayed on the medication. 然而,由于水平升高和妇产不良等副作用, 更多患者停止服用该药物. However, it caused more patients to stop taking the drug due to side effects like elevated potassium levels and gynecomastia. 需要进一步研究,以澄清其在心脏健康中的作用。 Further research is needed to clarify its role in heart health.